Frank KungManaging Partner
Vivo Capital

Dr. Kung is a founding member of Vivo Capital (formerly BioAsia Investments), a healthcare/biotechnology venture capital management firm in Palo Alto, California.
Dr. Kung started his career in the biotechnology industry in 1979 when he joined Cetus Corporation. He later co-founded Cetus Immune Corporation in 1981, which was acquired by its parent company in 1983. In 1984 he co-founded Genelabs Technologies, Inc. (NADSAQ: GNLB) where he served as Chairman and CEO until 1995. During his tenure in Genelabs, he brought the company public in 1991, and built it to a 175 employee international biotech company with operations in the United States, Belgium, Singapore, Switzerland and Taiwan.
Dr. Kung received his B.S. in chemistry from the National Tsing Hua University in Taiwan, his Ph.D. in molecular biology and M.B.A. from the University of California, Berkeley. He received the Best Use of Technology Award from the Governor of California, the Entrepreneur of the Year Awards from Ernst and Young, and the Asian Business League. He also served on the board of directors of the Emerging Company Governing Body of the Biotechnology Industry Organization (BIO); Mt. Jade Science and Technology Association, West Coast; and the Asian American Manufacturing Association. He was appointed by the U.S. Secretary of Health and Human Services as a voting member of the National Biotechnology Policy Board. Dr. Kung currently serves on the board of directors of a number of emerging healthcare and biotechnology companies.

Hongbo LuPartner
Lilly Asia Ventures

Dr. Hongbo Lu is a partner at Lilly Asia Ventures, a healthcare-focused investment firm with over USD$1.2 billion AUM. Previously, Dr. Lu was with OrbiMed Advisors, serving as its Managing Director in Asia, responsible for over $500m public equity investment portfolio in emerging markets, as well as led a few private equity investments and served as board of directors of private and public companies.

Dr. Lu has over 15 years of investment and operational experience in healthcare industry, including her tenures at OrbiMed, Piper Jaffray & Co. and life science start-up Zyomyx. Dr. Lu received a Ph.D. in BioEngineering from the University of Washington, an M.B.A. from the Haas School of Business at the University of California, Berkeley, and graduated with honor from Tsinghua University in China.

James LiCEO
JW Therapeutics

Currently James has been focusing on investing and building new life science companies that brings in cross-board breakthrough technologies and disruptive business models in China.
Until June 2015, Dr. James Li was a Vice President and the founding General Manager of Amgen China, where he led the company’s efforts in formulating a China entry strategy and established its presence in China to help patients gaining access to Amgen’s vital medicines.
Prior to joining Amgen, James was a Partner at Kleiner Perkins Caufield & Byers life science practice, worked both in the US and China funds. He successfully invested in a number of companies both in the US and China.
From 1991 to 2006, James spent over 15 years with Merck Co. & Inc. where he held leadership positions with increasing responsibilities in clinical research, regulatory affairs, new product development and franchise management, both in the US and Asia Pacific/China. During his tenure, he was instrumental in obtaining regulatory approvals of Merck vaccines across Asia Pacific Region when the Vaccine Division started operations in the region, successfully built the foundations of Merck’s medical operations in China and drove the success of Merck’s anti-hypertension franchise in Asia.
James received his Medical Degree from Shanghai Medical University followed by a Master of Science degree in Microbiology from the University of Montana.

Norman Chen Venture Partner
6 Dimensions Capital

Mr. Chen began his healthcare career at Baxter International, where he was responsible for the kidney dialysis business unit across Asia. In 1995, Mr. Chen founded Asia Renal Care, Ltd. to provide international-standard dialysis services in Asia, and led the company to become the leading independent dialysis group in Asia with over 70 centers in Taiwan, Singapore, the Philippines, Japan, Korea and Malaysia.

In 2002, Mr. Chen joined Walden International as Entrepreneur-in-Residence. In 2004, he co-founded DeltaHealth as a provider of international-quality cardiovascular care in China. DeltaHealth opened its first clinic in Shanghai in 2010 and a 200-bed cardiovascular hospital in 2016.

From 2005-2012, Mr. Chen led healthcare investing at Fidelity Growth Partners Asia (now called Eight Roads Ventures), where he was responsible for investments in several successful companies in China in the CRO, specialty pharmaceutical, medical device, medical service and other healthcare areas.

Mr. Chen is a Venture Partner at 6 Dimensions Capital, a leading US-China life sciences fund with $1 billion under management.

Mr. Chen is on the boards or advisory councils of the following non-profit organizations – Children’s Medical Foundation (HK), Marine Science Institute, and Positive Coaching Alliance.

Mr. Chen has a BS degree in Biology from the Massachusetts Institute of Technology and an MBA from Stanford University. He lives in the SF Bay Area.

Marietta WuManaging Director
Quan Capital

Dr. Marietta Wu’s experience ranges from clinical medicine and medical research to finance and entrepreneurship. She is currently Managing Director of Quan Capital, a premier life sciences venture fund backed by Zai Lab. She is a co-founder of Zai Lab and served as COO of the company. Prior to founding Zai Lab, she was Managing Director at Burrill & Company, leading Burrill’s investments and operation in Greater China, focusing on venture capital investing in China and Taiwan related life sciences opportunities. She serves on the board of Jing Medicine Technology, Kira Pharmaceutical and Qiagen (Suzhou) Translational Medicine Company, and was a board member of JHL Biotech(TWEM: 6540), Taiwan Liposome Company (GTSM: 4152) and General Biologics Corporation (TWEM: 4117). She also served as acting COO of Waterstone, a specialty pharmaceutical company with key operations in China. Over the past decade, she has been active in cross border ventures and value creation in the life sciences industry. Dr. Wu is a frequent speaker and author on China and Taiwan life sciences topics, and a founding member of the China Healthcare Investment Conference

Prior to her focus in healthcare investments, Dr. Wu was Director of Strategy at Edwards Lifesciences. She also held various financial and business development positions at Eli Lilly & Company.

Dr. Wu received her medical degree from Shanghai Jiaotong University School of Medicine (formerly Shanghai Second Medical University), a Ph.D. in Medical Sciences from Medical College of Ohio, and an MBA from the University of Michigan Ross School of Business.


Norman Chen Venture Partner, 6 Dimensions Capital
Frank KungManaging Partner, Vivo Capital
James Li CEO, JW Therapeutics
Hongbo LuPartner, Lilly Asia Ventures
Marietta WuManaging Director, Quan Capital
Cyber Cao Managing Director
Sequoia Capital China

Prior to joining Sequoia, Cyber participated most of the investment starting from Vivo Fund VII in China and served on the board of SMC and Gengmei APP. Before that, Cyber was the leader of Nycomed North Asia strategy and business development, and He helped Nycomed refurbish its China business and played an integral role in its acquisition of Techpool, a leading Chinese pharmaceutical player. In his early career, Cyber was at McKinsey & Company where he worked with both multi-national and local pharmaceutical companies on corporate strategy. Cyber received his M.S. in Pharmacy Administration and a B.S. in Pharmaceutics from Peking University.

Jialing DaiManaging Editor
PharmaDJ and RNDer

Mr. Dai currently is the managing editor at PharmaDJ and RNDer, two publications under WesternTide company that cofounded by him in 2014. Before founded these two publications in 2015, he worked for WuXi AppTec, a previously NYSE listed Chinese CRO company. At WuXi AppTec, he led a team to manage the company’s social media platform and media relationship.

Prior to joining WuXi AppTec in 2014, he was China Bureau Chief for PharmAsia News and Informa Business Intelligence (formerly Elsevier Business Intelligence), a global publisher that provides analysis and insight on the biopharma and medical devices industries. He spearheads regulatory, commercial and R&D coverage for both the pharmaceutical and medical device industry in China. He is also a member of the Organizing Committee to PharmAsia Summit, an annual strategic conference since 2009.

Prior to joining EBI in 2008, Mr. Dai was a journalist and analyst at Trombly Ltd., a media outlet that covered industry news in China on behalf of foreign trade press. During two years’ service at Trombly, he received journalism training and wrote articles for different foreign media including PharmAsia News, Securities Industry News, CardLine, Emerging China and related publications.

Jon Liong Managing Director
Lychee Group

Jon is the Founder and Managing Partner of Lychee Group, a company focused on creating the highest-quality events for China's life sciences industry.
Jon brings over 15 years of success in the strategic planning, organization and marketing of pharmaceutical and biotech business-to- business conferences.
In 1999, he joined Strategic Research Institute, a leading New York- based conference company. During his tenure there he organized and directed over 100 successful life sciences conferences and managed the production of over 40 events annually. As Managing Director, Jon led the company’s global expansion into China, conceiving and launching the "IMPACT CHINA: Pharmaceutical Global R&D" series, which was the first ever Western-organized conference covering China's life sciences industry.
Since starting Lychee, Jon has helped launch some of the highest profile healthcare events in China including "China Healthcare Investment Conference (CHIC)," "ChinaTrials: Global Clinical Development Summit," and "Asia Healthcare CEO Meeting by OrbiMed." Jon received his B.S. in Marketing from the New York University Stern School of Business.

Yuwen LiuFounding Partner
BOHE Angel Fund

Founding Partner of BOHE Angel Fund, a 200M RMB fund jointly invested by Wuxi Apptec, Hengrui, Simcere, TigerMed and BGI,etc. This is the first angel fund focusing on healthcare technology-driven start-ups in China, with Xiaodong Wang and Yigong Shi sitting on its scientific advisory board. It has invested into XinKangHe biological, Transcriptic, SmartNuclide, Athelas Therapeutics, CoolLing Biotech, and HighField BioPharmaceutical covering drug discovery, diagnostic and innovative service solutions.
Before she sets up this fund, she was Chairwoman & CEO then executive director of Suzhou Industrial Park Biotech Development Co. Ltd. (BioBAY) for 9 years, when she was also Investment Committee Member for BioVENTURE Fund, and Board Director of Innovent, Admera Health, Chiral Quest, GenePharma, Reproposing and BrightGene, and Chairwoman of Qiagen (Suzhou) Translational Medicine and Suzhou BioTOP Biotech. She joined the company as EVP in 2005, was instrumental in building BioBAY to be one of the fastest growing biotech clusters serving ~400 biotech startup companies.
She started her career as QA Engineer for Capsugel in 1997, then moved up to QC manager, QA/QC manager and BD manager. In 2003, she joined Perrigo as first Chief Representative to set up its China operation.
She graduated from China Pharmaceutical University with master degree in Pharmaceutics and Master of Management at Fudan University and Norwegian Management School BI. She is a licensed pharmacist.

Lawrence WangManaging Director
Vivo Capital

Lawrence Wang, M.D., M.B.A. is a Managing Director who joined Vivo Capital in 2015. Before joining Vivo, Lawrence was a Managing Director at Primavera Capital. At Primavera, he led and executed several investments including Chemspec International, Oasis International Hospital, Focus Media, Shanda Games and China XLX Fertilizer. Prior to Primavera, Lawrence was an Executive Director at Macquarie Capital where he was responsible for healthcare advisory and investments. At Macquarie, Lawrence led and executed Fortis’ $4.3bn SGD voluntary general offer for Parkway Holdings as well as Macquarie’s first bookrun NYSE IPO of China Cord Blood. Prior to Macquarie, Lawrence was an Executive Director at Goldman Sachs, responsible for private investments for GS Direct Asia, and healthcare investment banking coverage. Lawrence led and executed GS Direct Asia’s investment in Shenzhen Hepalink as well as the IPO’s of Mindray, Simcere and Nepstar. While in New York, he advised and executed on $3.7bn sellside of VWR International to MDP, Anthem’s $16bn acquisition of WellPoint, and WellPoint’s $6.5bn acquisition of WellChoice, among others.

Lawrence holds a Bachelor of Arts in Biology and Economics and a Doctor of Medicine from Boston University and an MBA from MIT Sloan School of Management.

Karen Wong Partner
Wilson Sonsini Goodrich & Rosati

Dr. Karen Wong is a life sciences IP partner at Wilson Sonsini Goodrich & Rosati. Her practice includes freedom- to-operate and due-diligence studies, patent preparation and prosecution, opinion work, litigation strategy, and technology licensing. Karen serves as IP counsel to many venture-backed companies, and has worked on numerous major strategic alliance transactions, acquisitions, spin-outs, and IPOs. Dr. Karen Wong is a life sciences IP partner at Wilson Sonsini Goodrich & Rosati. Her practice includes freedom- to-operate and due-diligence studies, patent preparation and prosecution, opinion work, litigation strategy, and technology licensing. Karen serves as IP counsel to many venture-backed companies, and has worked on numerous major strategic alliance transactions, acquisitions, spin-outs, and IPOs.
Prior to practicing law, Karen conducted doctoral and post-doctoral research at Harvard and Tufts Medical School in molecular biology, cell biology, and physiology. Karen is a co-founder and board member of BioE2E, which has built one of the largest communities of life sciences entrepreneurs in the Bay Area. A native of Sichuan, China, she is fluent in English, Mandarin, and Cantonese.


Copyright © 2018 Consortium of China Healthcare. All rights reserved